Peregrine Pharmaceuticals, Inc. - Investor Relations

Main menu module goes here

Search the Investors Section

Contact menu module goes here

Home > Investors > Investor Relations

Investor Relations

View all » Recent Releases

Jun 3, 2013
Encouraging Results in Breast and Pancreatic Cancers for Patients Treated With Peregrine's Novel Immunotherapy Bavituximab Presented at ASCO

Jun 3, 2013
Data Presented at ASCO Shows Promising 11.7 Month Median Overall Survival in Second-Line NSCLC Patients Treated With Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab

Transfer Agent
Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 Toll-Free: 866-232-0395 International: 720-358-3630 E-mail: shareholder@broadridge.com

Stock Quote

Ticker:	PPHM
Exchange:	NASDAQ
Last Price:	1.50
Change:	0.06
Volume:	1,414,600
Open:	1.57
Previous Close:	1.56

Contacts
Peregrine Pharmaceuticals, Inc. 14282 Franklin Avenue, Tustin, CA 92780 Phone: 714-508-6000 Fax: 714-838-5817 info@peregrineinc.com	Investor Relations/Corporate Communications info@peregrineinc.com Phone: 800-987-8256

Print

E-mail

Copyright © 2003-2013 Peregrine Pharmaceuticals Inc., All Rights Reserved	Disclaimer Safe Harbor